Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avita Medical Ltd.

5.16
-0.1400-2.64%
Post-market: 5.160.00000.00%16:58 EDT
Volume:321.03K
Turnover:1.66M
Market Cap:137.07M
PE:-2.36
High:5.46
Open:5.29
Low:5.06
Close:5.30
Loading ...

AVITA Medical Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
07 May

AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

GlobeNewswire
·
24 Apr

AVITA Medical to Announce First Quarter 2025 Financial Results

GlobeNewswire
·
18 Apr

Avita Medical Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Apr

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

GlobeNewswire
·
10 Apr

Avita Medical Is Maintained at Buy by D. Boral Capital

Dow Jones
·
04 Apr

AVITA Medical Inc Announces U.S. Commercial Launch Of Cohealyx

Reuters
·
04 Apr

AVITA Medical Launches Wound Care Product Cohealyx in US

MT Newswires Live
·
04 Apr

Avita Medical (RCEL) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
18 Mar

Avita Medical Is Maintained at Buy by D. Boral Capital

Dow Jones
·
18 Mar

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

GlobeNewswire
·
18 Mar

Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

Zacks
·
13 Mar

Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel

Simply Wall St.
·
07 Mar

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

GlobeNewswire
·
27 Feb

AVITA Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
15 Feb

AVITA Medical to Host Investor Webinar Briefing

GlobeNewswire
·
14 Feb

Lake Street Remains a Buy on Avita Medical (RCEL)

TIPRANKS
·
14 Feb

Avita Medical Is Maintained at Buy by D. Boral Capital

Dow Jones
·
14 Feb

Analysts Conflicted on These Healthcare Names: Cochlear Limited (OtherCHEOF) and Avita Medical (RCEL)

TIPRANKS
·
14 Feb

AVITA Medical Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb